Wendell Wierenga Sells 20,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Wendell Wierenga sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the completion of the sale, the director directly owned 32,444 shares in the company, valued at $2,145,846.16. This represents a 38.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Wendell Wierenga also recently made the following trade(s):

• On Monday, October 27th, Wendell Wierenga sold 4,375 shares of Cytokinetics stock. The stock was sold at an average price of $58.68, for a total transaction of $256,725.00.

Cytokinetics Stock Up 0.9%

Shares of CYTK opened at $63.86 on Thursday. Cytokinetics, Incorporated has a fifty-two week low of $29.31 and a fifty-two week high of $70.98. The company’s fifty day moving average is $62.89 and its two-hundred day moving average is $49.20. The firm has a market cap of $7.81 billion, a PE ratio of -10.15 and a beta of 0.58.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.59) by $0.05. The firm had revenue of $1.94 million for the quarter, compared to analyst estimates of $6.05 million. During the same quarter in the previous year, the company earned ($1.36) earnings per share. The company’s quarterly revenue was up 318.1% on a year-over-year basis. As a group, equities research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Institutional Trading of Cytokinetics

Hedge funds have recently made changes to their positions in the company. Deep Track Capital LP boosted its stake in shares of Cytokinetics by 17.8% in the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after purchasing an additional 650,000 shares during the period. Geode Capital Management LLC increased its stake in Cytokinetics by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 2,994,445 shares of the biopharmaceutical company’s stock worth $98,948,000 after buying an additional 56,961 shares during the period. Vestal Point Capital LP boosted its position in Cytokinetics by 14.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock valued at $98,294,000 after buying an additional 384,469 shares during the last quarter. Woodline Partners LP boosted its position in Cytokinetics by 676.1% in the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock valued at $90,559,000 after buying an additional 1,435,422 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Cytokinetics by 2.0% during the third quarter. Northern Trust Corp now owns 1,406,832 shares of the biopharmaceutical company’s stock valued at $77,319,000 after acquiring an additional 27,641 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Stifel Nicolaus boosted their target price on Cytokinetics from $87.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Morgan Stanley lifted their price target on shares of Cytokinetics from $65.00 to $71.00 and gave the company an “overweight” rating in a research report on Monday. Wall Street Zen lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Leerink Partners set a $83.00 target price on shares of Cytokinetics in a research note on Monday. Finally, B. Riley reaffirmed a “buy” rating and set a $90.00 price target (up from $80.00) on shares of Cytokinetics in a research report on Monday, November 10th. Fifteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Cytokinetics currently has an average rating of “Moderate Buy” and an average target price of $83.61.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Major commercial catalyst — the company’s cardiology drug Myqorzo (aficamten) received FDA approval, moving Cytokinetics into a commercial‑stage biotech with an immediate revenue runway; this is the primary bullish driver. Article Title
• Positive Sentiment: Analyst support and price‑target lifts — several brokers have raised price targets and reiterated Buy/Outperform stances (Citizens/JMP raised to $88; Needham, Morgan Stanley and others maintaining favorable ratings), reinforcing upside expectations from the commercial launch. Article Title Article Title
• Positive Sentiment: Options flow: unusually heavy call buying (large block activity) suggests traders are positioning for further upside around the news and near‑term catalysts. Article Title
• Neutral Sentiment: HC Wainwright trimmed Q4 and FY2025 EPS estimates slightly (small downward revisions) but kept a Buy rating and a $136 price target — a modest near‑term negative to estimates but not a change in conviction. (Research note summarized by MarketBeat)
• Neutral Sentiment: Short‑interest report shows effectively zero reported short interest for December (likely a data anomaly); does not meaningfully change the supply/demand picture today.
• Negative Sentiment: Insider selling — director Wendell Wierenga sold 20,000 shares at ~$66.14 on Dec. 22 (SEC Form 4 filed). Insider sales can be read as a cautionary signal by some investors even if they’re for diversification/liquidity reasons. SEC Filing Article Title

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.